2630 — Vigonvita Life Sciences Co Balance Sheet
0.000.00%
Last trade - 00:00- HK$10.06bn
- HK$10.52bn
- KR₩12m
Annual balance sheet for Vigonvita Life Sciences Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | — | — |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Cash | ||
| Cash and Short Term Investments | 96 | 121 |
| Net Total Accounts Receivable | ||
| Net Total Receivables | 62.5 | 27.1 |
| Total Inventory | ||
| Prepaid Expenses | ||
| Total Other Current Assets | ||
| Total Current Assets | 166 | 159 |
| Gross Property, Plant And Equipment | ||
| Accumulated Depreciation | ||
| Net Property, Plant And Equipment | 436 | 487 |
| Net Intangible Assets | ||
| Long Term Notes Receivable | ||
| Other Long Term Assets | ||
| Total Assets | 676 | 726 |
| Accounts Payable | ||
| Accrued Expenses | ||
| Notes Payable / Short Term Debt | ||
| Current Portion of Long Term Debt / Capital Leases | ||
| Total Other Current Liabilities | ||
| Total Current Liabilities | 286 | 322 |
| Long Term Debt | ||
| Capital Lease Obligations | ||
| Total Long Term Debt | ||
| Total Debt | ||
| Minority Interest | ||
| Total Other Liabilities | ||
| Total Liabilities | 477 | 576 |
| Common Stock | ||
| Additional Paid In Capital | ||
| Retained Earnings (Accumulated Deficit) | ||
| Other Equity | ||
| Total Equity | 199 | 150 |
| Total Liabilities & Shareholders' Equity | 676 | 726 |
| Total Common Shares Outstanding |